TRCT
GPCR icon

Tower Research Capital (TRC)’s Structure Therapeutics GPCR Stock Holding History

Tower Research Capital (TRC)’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$48.1K Buy
897
+251
+39% +$11.1K ﹤0.01% 2768
2026
Q1 		$31.1K Buy
646
+605
+1,476% +$41.4K ﹤0.01% 3138
2025
Q4 		$2.85K Sell
41
-353
-90% -$14.4K ﹤0.01% 4465
2025
Q3 		$11K Sell
394
-504
-56% -$10K ﹤0.01% 3923
2025
Q2 		$18.6K Buy
898
+303
+51% +$6.66K ﹤0.01% 3723
2025
Q1 		$10.3K Sell
595
-3,481
-85% -$85.3K ﹤0.01% 3656
2024
Q4 		$111K Buy
4,076
+3,549
+673% +$126K ﹤0.01% 2098
2024
Q3 		$23.1K Buy
527
+158
+43% +$6.11K ﹤0.01% 3162
2024
Q2 		$14.5K Buy
369
+81
+28% +$3.33K ﹤0.01% 3944
2024
Q1 		$12.3K Sell
288
-775
-73% -$32.7K ﹤0.01% 3489
2023
Q4 		$43.3K Buy
1,063
+142
+15% +$8.14K ﹤0.01% 3223
2023
Q3 		$46.4K Buy
921
+854
+1,275% +$27.5K ﹤0.01% 2611
2023
Q2 		$2.79K Sell
67
-33
-33% -$925 ﹤0.01% 5152
2023
Q1 		$2K Buy
+100
New +$2.35K ﹤0.01% 5352

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Tower Research Capital (TRC)'s GPCR Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Structure Therapeutics (GPCR) stake by 39% in Q2 2026, buying an estimated $11.1K and bringing the position to 897 shares worth $48.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2768.

Tower Research Capital (TRC) first reported a position in GPCR in Q1 2023 and has held it in 14 quarters since. The position peaked at $111K in Q4 2024. 191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Tower Research Capital (TRC) held 897 shares of Structure Therapeutics worth $48.1K as of Q2 2026.
  • Tower Research Capital (TRC) bought 251 Structure Therapeutics shares in Q2 2026, an estimated $11.1K.
  • Structure Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2768 holding.
  • Tower Research Capital (TRC) first reported a position in Structure Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Tower Research Capital (TRC)'s Structure Therapeutics position peaked at $111K in Q4 2024.
  • 191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.